Latest Regulatory News

Health Canada has requested additional information, extending its review of CLINUVEL’s SCENESSE® for erythropoietic protoporphyria (EPP) into 2026. Meanwhile, Canadian patients continue to access the treatment via a Special Access Program.

Aspen Group has upgraded its FY26 pre-tax earnings guidance by 6%, driven by strong rental income growth and development profits amid Australia's acute housing shortage. The company also announces a strategic acquisition of a new Sydney headquarters.

Ark Mines has secured Environmental Authority approval for its Sandy Mitchell Rare Earths project in Queensland, marking a crucial step towards obtaining its Mining Licence. The company has also completed a major drilling program, setting the stage for an upcoming Pre-Feasibility Study.

PolyNovo Limited has appointed Bruce Peatey as its new CEO, bringing extensive international healthcare experience to drive the company’s next growth phase. Peatey’s leadership is expected to accelerate PolyNovo’s expansion into new markets and outpatient care.

Santana Minerals has taken a major step forward by acquiring freehold ownership of critical lands and extinguishing royalties at its Bendigo-Ophir Gold Project, enhancing project economics amid a strong gold market.

Liberty Metals has secured an option to acquire three strategically located critical mineral projects in Brazil, targeting high-purity rutile and rare earth elements. This move positions the company in a Tier 1 mining jurisdiction with promising exploration upside.

Firebrick Pharma has secured a $102,000 investment from its Philippines strategic partner, Pharma Nutria N.A., Inc., reinforcing its position ahead of the Nasodine nasal spray launch in 2026.

Toubani Resources has achieved a crucial regulatory milestone with the Environmental and Social Impact Assessment approval for its Kobada Gold Project in Mali, paving the way for on-site development activities.

Manhattan Corporation advances a high-resolution magnetic survey at its Hook Lake gold project in Nunavut while agreeing to sell its L3 Lithium Project in Nova Scotia for up to $1.34 million.

Anteris Technologies has secured its first European regulatory clearance to commence the global PARADIGM Trial for its DurAVR Transcatheter Heart Valve, marking a significant step toward worldwide commercialization.

Clarity Pharmaceuticals has inked a pivotal supply agreement with Nusano to ensure a steady source of copper-67, a critical isotope for its upcoming Phase III prostate cancer trial and future commercialisation plans.

TrivarX Limited has announced the acquisition of Stabl-Im, a novel stable isotope MRI technology for early brain tumor detection, backed by a $4.2 million capital raise including investment from biotech leader Dr Daniel Tillett.